Table 1 Study cohort characteristics are stratified by respiratory failure in patients with acute exacerbation of COPD

Age^a

48

66.0(62.3,72.8)

76

70.0(63.3,73.0)

0.13

Female gender^b

39

81.3%

65

85.5%

0.62

BMI^a

48

20.8(17.3,22.4)

76

21.2(18.4,22.9)

0.18

Smoking Index ^a

48

600(0,975)

76

675(363,1350)

0.32

Duration of COPD^a

48

13(6,29)

76

10(6,20)

0.31

Comorbidities^b

24

50.0%

41

53.9%

0.71

Diabetes mellitus^b

7

14.6%

7

9.2%

0.39

Coronary disease^b

3

6.3%

5

6.6%

1.00

Stroke^b

0

0%

3

3.9%

0.28

Hypertension^b

21

43.8%

37

48.7%

0.71

Home oxygen therapy^b

26

54.2%

20

26.3%

0.002

Regular medication^b

29

60.4%

40

52.6%

0.46

Oral glucocorticoid therapy^b

3

6.3%

2

2.6%

0.37

Theophylline therapy^b

1

2.1%

1

1.3%

1.00

Expectorants therapy^b

16

33.3%

18

23.7%

0.30

Inhaled COPD therapy^b

-

-

-

0.25

No inhaled treatment^b

5

10.4%

15

19.7%

LAMA^b

3

6.3%

6

7.9%

ICS + LABA^b

5

10.4%

15

19.7%

LABA + LAMA^b

7

14.6%

9

11.8%

ICS + LABA + LAMA^b

28

58.3%

31

40.8%

SGRQ score^a

48

50.5(35.1,74.1)

76

37.2(25.4,58.5)

0.003

mMRC score^a

48

2(1,3)

76

1(1,3)

0.006

Exercise capacity score^a

48

2(1,2)

76

1(1,2)

0.003

CAT score^a

48

26(21,32)

76

19(13,26)

0.0002

COPD-related exacerbation within the previous year^a

48

1(0,2)

76

0(0,1)

0.019